INmune Bio, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $64.4M
- Price
- $2.32
- % Change (Daily % change from the live per-ticker quote feed.)
- +7.41%
- Volume
- 520.1K
About
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Quick stats
Shares outstanding27.8M
Computed float23.6M
Float / shares85.1%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001711754
Websitehttps://www.inmunebio.com
AI Summary
AI-generated1/28
majorbullishearnings
INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress
INmune Bio reported a Q2 net loss of $1.3 million, a significant improvement from the prior year's $24.5 million loss, largely due to a $4.2 million Australian R&D tax rebate recognized during the quarter.
Operationally, the company secured FDA Fast Track designation for XPro in early Alzheimer's disease and reported statistically significant MRI biomarker data, while Ebstrocel achieved MHRA alignment and commercial manufacturing milestones for its RDEB program.
The company ended the quarter with $18.4 million in cash and plans to submit a UK MAA for Ebstrocel in late 2026, followed by a US BLA and an EU MAA in early 2027.
Red flags
- Cash balance of $18.4M remains tight for multiple upcoming regulatory submissions and late-stage trials
- No revenue generated for the period